Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells

Table 1 Patient Demographics

Sample #	Cancer Status	Pack Years	Sex	Age Range	Smoking Status	Diagnosis
946	CA	45	F	50–59	Former	NSCLC-SQ
167	CA	50	F	60–69	Unknown	NSCLC
947	CA	45	M	60–69	Former	SCLC
146	CA	46.5	F	60–69	Former	NSCLC
887	CA	28	F	70–79	Current	NSCLC-AD
885	CA	90	M	70–79	Current	SCLC
940	CA	60	M	70–79	Former	NSCLC-AD
191	CA	NA*	M	70–79	Current	NSCLC-SQ
147	CA	75	M	70–79	Former	SCLC
128	CA	40	F	50–59	Current	NSCLC
923	CA	15	M	70–79	Former	NSCLC
210	NC	34	M	40–49	Current	Noncancer
886	NC	0	F	40–49	Never	Noncancer
952	NC	30	M	50–59	Former	Noncancer
157	NC	100	M	60–69	Unknown	Noncancer
943	NC	0	F	60–69	Never	Noncancer
956	NC	20	M	60–69	Current	Noncancer
884	NC	54	M	70–79	Former	Noncancer
883	NC	0	M	80–89	Never	Noncancer

*Not available: The exact pack year smoking history for this patient was not recorded. However, it was recorded that the patient was an active 2 PPD smoker at time of lung cancer diagnosis at age 75 and had advanced stage COPD, thus there is compelling circumstantial evidence for large smoking history

ISSN: 1471-2407